Compare CFLT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CFLT | LEGN |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 5.9B |
| IPO Year | 2021 | 2020 |
| Metric | CFLT | LEGN |
|---|---|---|
| Price | $29.96 | $22.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 13 |
| Target Price | $29.93 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 19.6M | 2.6M |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,113,149,000.00 | $909,045,000.00 |
| Revenue This Year | $22.76 | $68.83 |
| Revenue Next Year | $16.57 | $51.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 21.57 | ★ 74.75 |
| 52 Week Low | $15.64 | $21.19 |
| 52 Week High | $37.90 | $45.30 |
| Indicator | CFLT | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 77.11 | 30.88 |
| Support Level | $29.95 | $21.19 |
| Resistance Level | $30.07 | $28.97 |
| Average True Range (ATR) | 0.27 | 1.23 |
| MACD | 0.23 | -0.13 |
| Stochastic Oscillator | 96.54 | 16.97 |
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.